PP_1170x120_10-25-21

ymptoms of opioid withdrawal

FDA approves US WorldMeds’ Lucemyra for opioid withdrawal symptoms

FDA approves US WorldMeds’ Lucemyra for opioid withdrawal symptoms

LOUISVILLE, Ky. — US WorldMeds  announced that the U.S. Food and Drug Administration (FDA) approved Lucemyra (lofexidine) for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. The FDA reviewed Lucemyra under Priority Review, which is granted to submissions for medications that would provide significant improvements in the safety or effectiveness of

Adheris Health